Photodynamic Therapy: A Prospective Therapeutic Approach for Viral Infections and Induced Neoplasia

Pharmaceuticals (Basel). 2022 Oct 16;15(10):1273. doi: 10.3390/ph15101273.

Abstract

The recent COVID-19 pandemic outbreak and arising complications during treatments have highlighted and demonstrated again the evolving ability of microorganisms, especially viral resistance to treatment as they develop into new and strong strains. The search for novel and effective treatments to counter the effects of ever-changing viruses is undergoing. Although it is an approved procedure for treating cancer, photodynamic therapy (PDT) was first used against bacteria and has now shown potential against viruses and certain induced diseases. PDT is a multi-stage process and uses photosensitizing molecules (PSs) that accumulate in diseased tissues and eradicates them after being light-activated in the presence of oxygen. In this review, studies describing viruses and their roles in disrupting cell regulation mechanisms and signaling pathways and facilitating tumorigenesis were described. With the development of innovative "or smart" PSs through the use of nanoparticles and two-photon excitation, among other strategies, PDT can boost immune responses, inactivate viral infections, and eradicate neoplastic cells. Visualization and monitoring of biological processes can be achieved in real-time with nanomedicines and better tissue penetration strategies. After photodynamic inactivation of viruses, signaling pathways seem to be restored but the underlying mechanisms are still to be elucidated. Light-mediated treatments are suitable to manage both oncogenic viral infections and induced neoplasia.

Keywords: immunity; nanomaterials; neoplasia; oncogenic viruses; photodynamic inactivation; photodynamic therapy; signaling pathways.

Publication types

  • Review

Grants and funding

We acknowledge the support provided by the “Centre International de Recherches Médicales de Franceville” (CIRMF) in Gabon, grant number: 047/2022/MESRSTTCA/MSAS/CIRMF/SF/RA/DG/JBLD.